A molecular basis for tetramer destabilization and aggregation of transthyretin Ala97Ser
暂无分享,去创建一个
C. Chao | S. Tzeng | Shing‐Jong Huang | G. Liou | Hsueh-Wen Hsueh | S. Hsieh | Hsi-Ching Tseng | Yi-Shiang Wang | Chun-Hsiang Huang | Chi-Ting Liang | Chun‐Hsiang Huang
[1] Salvador Ventura,et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity , 2016, Nature Communications.
[2] A. Corazza,et al. Calcium Binds to Transthyretin with Low Affinity , 2022, Biomolecules.
[3] Y. Jeng,et al. Unique Phenotypes With Corresponding Pathology in Late-Onset Hereditary Transthyretin Amyloidosis of A97S vs. V30M , 2022, Frontiers in Aging Neuroscience.
[4] E. Papaleo,et al. Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation , 2021, The Journal of biological chemistry.
[5] S. Gottlieb,et al. Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS) , 2021, Neurology and Therapy.
[6] Y. Vorasettakarnkij,et al. Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort , 2021, BMC Neurology.
[7] H. Lv,et al. Hereditary transthyretin amyloidosis in mainland China: a unicentric retrospective study , 2021, Annals of clinical and translational neurology.
[8] M. Schupp,et al. Biological Functions of RBP4 and Its Relevance for Human Diseases , 2021, Frontiers in Physiology.
[9] L. Lopiano,et al. Safety and efficacy of tolcapone in Parkinson’s disease: systematic review , 2021, European Journal of Clinical Pharmacology.
[10] M. Saraiva,et al. Modulation of the Mechanisms Driving Transthyretin Amyloidosis , 2020, Frontiers in Molecular Neuroscience.
[11] S. Kędracka-Krok,et al. Destabilisation of the structure of transthyretin is driven by Ca2. , 2020, International journal of biological macromolecules.
[12] M. Mizuguchi,et al. Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments. , 2020, Journal of medicinal chemistry.
[13] R. Griffin,et al. Disruption of the CD loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway. , 2020, Biochemistry.
[14] A. Velázquez‐Campoy,et al. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis , 2020, The FEBS journal.
[15] C. Sommer,et al. Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease. , 2020, Deutsches Arzteblatt international.
[16] A. Pelayo-Negro,et al. Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review. , 2019, European journal of hospital pharmacy : science and practice.
[17] K. Chien,et al. Cardiac manifestations and prognostic implications of hereditary transthyretin amyloidosis associated with transthyretin Ala97Ser. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.
[18] Chih-Chiang Chan,et al. Cellular secretion and cytotoxicity of transthyretin mutant proteins underlie late-onset amyloidosis and neurodegeneration , 2019, Cellular and Molecular Life Sciences.
[19] M. Waddington‐Cruz,et al. Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry , 2019, Journal of the Neurological Sciences.
[20] M. Slama,et al. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease , 2019, Nature Reviews Neurology.
[21] Yi-Chung Lee,et al. Clinical and genetic profiles of hereditary transthyretin amyloidosis in Taiwan , 2019, Annals of clinical and translational neurology.
[22] Whei-Min Lin,et al. Skin nerve pathology: Biomarkers of premanifest and manifest amyloid neuropathy , 2019, Annals of neurology.
[23] Yanguo Xin,et al. Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systematic Review and Meta-Analysis , 2018, Journal of clinical neurology.
[24] S. Hsieh,et al. Sensory nerve degeneration in a mouse model mimicking early manifestations of familial amyloid polyneuropathy due to transthyretin Ala97Ser , 2018, Neuropathology and applied neurobiology.
[25] H. Dyson,et al. NMR Measurements Reveal the Structural Basis of Transthyretin Destabilization by Pathogenic Mutations. , 2018, Biochemistry.
[26] O. Gursky,et al. Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease , 2018, Proceedings of the National Academy of Sciences.
[27] J. Hsu,et al. Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis. , 2018, Journal of visualized experiments : JoVE.
[28] D. Adams,et al. Familial amyloid polyneuropathy , 2017, Current opinion in neurology.
[29] M. de Carvalho,et al. Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation , 2017, Scientific Reports.
[30] C. Chao,et al. The Temporal Profiles of Changes in Nerve Excitability Indices in Familial Amyloid Polyneuropathy , 2015, PloS one.
[31] D. Hirschberg,et al. Considerably Unfolded Transthyretin Monomers Preceed and Exchange with Dynamically Structured Amyloid Protofibrils , 2015, Scientific Reports.
[32] Lei Z. Robinson,et al. Quantification of Quaternary Structure Stability in Aggregation-Prone Proteins under Physiological Conditions: The Transthyretin Case , 2014, Biochemistry.
[33] C. Robinson,et al. Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis , 2014, Proceedings of the National Academy of Sciences.
[34] E. Nordh,et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. , 2013, JAMA.
[35] I. Graef,et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin , 2013, Proceedings of the National Academy of Sciences.
[36] I. Merkies. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial , 2013, Neurology.
[37] H. Dyson,et al. Localized structural fluctuations promote amyloidogenic conformations in transthyretin. , 2013, Journal of molecular biology.
[38] M. Saraiva,et al. Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin , 2012, FEBS letters.
[39] S. Hsieh. Amyloid neuropathy with transthyretin mutations: overview and unique Ala97Ser in Taiwan. , 2011, Acta neurologica Taiwanica.
[40] L. Cendron,et al. Structural and mutational analyses of protein–protein interactions between transthyretin and retinol‐binding protein , 2008, The FEBS journal.
[41] Yi-Chung Lee,et al. Transthyretin Ala97Ser in Chinese–Taiwanese patients with familial amyloid polyneuropathy: Genetic studies and phenotype expression , 2008, Journal of the Neurological Sciences.
[42] Steven M. Johnson,et al. Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. , 2008, Journal of medicinal chemistry.
[43] C. Waters,et al. Role of tolcapone in the treatment of Parkinson’s disease , 2007, Expert review of neurotherapeutics.
[44] K. Henrick,et al. Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.
[45] T. Aizawa,et al. Destabilization of transthyretin by pathogenic mutations in the DE loop , 2006, Proteins.
[46] J. Kelly,et al. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression , 2006, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[47] Steven M. Johnson,et al. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. , 2005, Accounts of chemical research.
[48] J. Kelly,et al. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[49] James C Sacchettini,et al. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. , 2004, Journal of medicinal chemistry.
[50] G. Zanotti,et al. Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin. , 2004, Vitamins and hormones.
[51] O. Suhr. Impact of liver transplantation on familial amyloidotic polyneuropathy (FAP) patients' symptoms and complications , 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[52] M. Lei,et al. Why is Leu55→Pro55 transthyretin variant the most amyloidogenic: Insights from molecular dynamics simulations of transthyretin monomers , 2003, Protein science : a publication of the Protein Society.
[53] T. Tokuda,et al. Energetic Characteristics of the New Transthyretin Variant A25T May Explain Its Atypical Central Nervous System Pathology , 2003, Laboratory Investigation.
[54] J. Kelly,et al. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[55] J. Kelly,et al. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[56] J. Kelly,et al. Support for the multigenic hypothesis of amyloidosis: The binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[57] A. Olofsson,et al. A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. , 2000, Journal of molecular biology.
[58] D. Booth,et al. Transthyretin Ala97Ser is associated with familial amyloidotic polyneuropathy in a Chinese‐Taiwanese family , 2000, Human mutation.
[59] H. Ideta,et al. A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels. , 1999, Biochemical and biophysical research communications.
[60] C. Wurth,et al. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. , 1999, Biochemistry.
[61] J. Kelly,et al. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. , 1998, Biochemistry.
[62] J. Kelly,et al. Recombinant human retinol-binding protein refolding, native disulfide formation, and characterization. , 1998, Protein expression and purification.
[63] J. Kelly,et al. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. , 1996, Biochemistry.
[64] P. Argos,et al. Knowledge‐based protein secondary structure assignment , 1995, Proteins.
[65] A Coda,et al. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. , 1995, Science.
[66] J. Phang,et al. Production of human plasma retinol-binding protein in Escherichia coli. , 1993, Gene.
[67] J. Hamilton,et al. The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolution. , 1993, The Journal of biological chemistry.
[68] P. Albertsson,et al. Interaction between prealbumin and retinol-binding protein studied by affinity chromatography, gel filtration and two-phase partition. , 1979, European journal of biochemistry.
[69] P. A. Peterson,et al. Studies on thyroid hormone-binding proteins. II. Binding of thyroid hormones, retinol-binding protein, and fluorescent probes to prealbumin and effects of thyroxine on prealbumin subunit self association. , 1975, The Journal of biological chemistry.
[70] Howard C. Berg,et al. Genetic analysis , 1957, Nature Biotechnology.